10x Genomics, Inc. TXG Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Spatial | $40.91M-0.1% | $40.96M+15.8% | $35.37M-2.8% | $36.4M+16.5% | $31.25M-12.7% | |
| Revenue by Product | ||||||
| Chromium | $88.89M— | —— | $92.52M+7.8% | $85.79M+2.0% | $84.11M-13.9% | |
| License and royalty revenue | $947K+178% | $341K-65.3% | $983K-96.5% | $27.75M+62.7% | $17.06M+15,269% | |
| Products and services revenue | $149.9M-9.5% | $165.69M+11.9% | $148.02M+2.0% | $145.16M+5.3% | $137.82M-16.4% | |
| Services | $8.83M+4.3% | $8.47M+4.2% | $8.13M-4.1% | $8.48M+10.8% | $7.65M+8.9% | |
| Single Cell | $5.22M— | —— | $4.93M-14.0% | $5.73M-3.1% | $5.91M-45.9% | |
| Spatial | $6.04M-35.5% | $9.36M+32.4% | $7.07M-19.4% | $8.77M-1.5% | $8.9M-33.7% | |
| Revenue by Geography | ||||||
| Americas (excluding United States) | $3.41M+5.9% | $3.22M+22.6% | $2.63M-1.6% | $2.67M-28.9% | $3.75M+27.8% | |
| Asia-Pacific (excluding China) | $18.06M+17.5% | $15.37M+24.8% | $12.32M+39.2% | $8.85M-43.1% | $15.54M+16.3% | |
| China | $15.84M+5.4% | $15.02M-1.1% | $15.19M-34.4% | $23.17M+37.2% | $16.88M+15.6% | |
| Europe, Middle East and Africa | $36.85M-31.1% | $53.46M+28.4% | $41.62M+19.8% | $34.73M+8.9% | $31.9M-36.0% | |
| United States | $76.69M-2.9% | $78.96M+2.2% | $77.25M-25.4% | $103.49M+19.2% | $86.82M+3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does 10x Genomics, Inc. break its business down?
- 10x Genomics, Inc. (TXG) reports total revenue by product across 2 parts — Single Cell and Spatial. Each is extracted from the segment footnotes and tracked over time.
- Where does 10x Genomics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in 10x Genomics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.